Key result
Obesity-related heart failure with preserved ejection fraction is a distinct phenotype with unique pathophysiology, for which SGLT2 inhibitors have emerged as a promising therapeutic option.
Why the study?
Obesity-related HFpEF is a distinct, frequent phenotype with complex diagnosis, and its management has not been established despite promising drugs.
Obesity-related HFpEF presents unique diagnostic challenges due to lower natriuretic peptide levels and poor echocardiographic windows, but SGLT2 inhibitors and MRAs offer promising targeted therapeutic options.
May inform SGLT2 inhibitor selection in obesity-related HFpEF; leaves open confirmation in prospective trials.
The prevalence of heart failure with preserved ejection fraction (HFpEF) has increased in recent decades. In particular, obesity-related HFpEF is a distinct and frequently encountered phenotype; however, its diagnosis is complex. Furthermore, the management of obesity-related HFpEF has not been established despite the introduction of promising drugs. This review summarizes the diagnostic challenges, pathophysiology, and therapeutic options for obesity-related HFpEF.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2023) conducted a review in Obesity-related heart failure with preserved ejection fraction (HFpEF). SGLT2 inhibitors, MRAs, and bariatric surgery was evaluated. Obesity-related heart failure with preserved ejection fraction is a distinct phenotype with unique pathophysiology, for which SGLT2 inhibitors have emerged as a promising therapeutic option.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: